重组组织纤溶酶原激活剂在急性脑梗死溶栓治疗中的应用

Thrombolytic therapy in acute cerebral infarction with recombinant tissue plasminogen activator

目的评价急性脑梗死患者采用重组组织型纤溶酶原激活剂(rt-PA)溶栓后疗效。方法对符合纳入标准的脑梗死患者进行rt-PA溶栓后,观察临床疗效。结果 21例符合标准的急性脑梗死患者接受rt-PA溶栓治疗,临床症状整体有好转,溶栓后美国国立卫生研究院脑卒中量表(NIHSS)评分有改善,于24h后观察差异有统计学意义;治疗后有2例出现继发脑出血;有2例分别死于脑出血和脑疝。结论 rt-PA溶栓是治疗急性脑梗死的有效选择,严格掌握溶栓指征,可以控制并发症的发生,值得在临床中推广。

Objective To evaluate the clinical outcomes of thrombolytic therapy in acute cerebral infarction with recombinant tissue plasminogen activator（rt-PA）.Methods The patients enrolled was treated with rt-PA thrombolytic therapy and analysis of the clinical outcomes.Results 21 selected patients with acute cerebral infarction underwent thrombolytic therapy with rt-PA,and demonstrated efficacy in improving clinical outcomes.The National Institutes of Health Stroke Scale（NIHSS）of witch is improvement as opposed to pre-therapy;Two bleeding events happened after thrombolysis,and two patients were dead with cerebral bleeding or hernia.Conclusion Thrombolysis with rt-PA may induce a favorable clinical outcome for the treatment of acute cerebral infarction.To suitable patients,thrombolysis is a safe procedure,The complications of which is acceptable.